[Clinical trial of loxapine succinate in the treatment of 30 cases of psychotic states].
An open clinical study of loxapine succinate was developed on 30 hospitalized psychiatric patients in order to confirm its antipsychotic properties and its originality opposite the other major neuroleptics. Dosages ranged from 100 to 200 mg per day in 12 cases (40%), and more than 200 mg in serious psychosis or unamenable to therapeutic for which inferior dosages were inefficacious (11 cases). 56,7% of favourable results have been obtained, with a fair improvement of whole symptoms, paranoïd schizophrenic attack and acute delusions. Tolerance was remarkable: no neuro-vegetative manifestation was reported. The considerable sedative effect of loxapine had involved moderate and no invalidating drowsiness in 23% of cases. The extra-pyramidal occurring symptoms disappeared within 2 or 3 days. So loxapine succinate in proving to be a major first intention neuroleptic, suiting a considerable antipsychotic efficacy to a good tolerance, allowing new perspectives in the therapeutic and the approach of psychotic patients.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003702:Delusions / Q000188:drug therapy; D003989:Dibenzoxazepines / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D005260:Female; D006801:Humans; D008152:Loxapine / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011618:Psychotic Disorders / Q000150:complications / Q000188:drug therapy*; D012559:Schizophrenia / Q000188:drug therapy
D003989:Dibenzoxazepines; D008152:Loxapine
Essai clinique du succinate de loxapine appliqué au traitement de 30 cas d'états psychotiques.